A Phase 3 interventional study of ZD4054 and Palcebo in Prostate Cancer, sponsored by AstraZeneca. Terminated at 330 sites in 39 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 3rd largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2008, is one of 17 in phase 3, and was the 18th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Austria, Brazil and 18 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Australia, Germany and 4 more countries
Ages 18–99 · Men only
AstraZeneca · Sites in United States, Australia, Korea, Republic of
Ages 18–100 · Men only
AstraZeneca · Sites in United States, Australia, Austria and 21 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Brazil, China and 7 more countries
Ages 18–130 · Men only
By country, each count listing its studies:
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 27 · Phase 3 17 · Phase 4 4
First in 1994; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,577 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 110 across the 60 interventional studies, 310 across the 29 observational. Of the 58 that completed or were terminated, 11 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
8 of the studies in Prostatic Neoplasms by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06120491Phase 3AstraZenecaSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | 2027-09-30 |
| NCT06267729AstraZenecaStudy of AZD0754 in Participants With Metastatic Prostate Cancer | 2026-11-24 |
| NCT06402331Fusion Pharmaceuticals Inc.FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2026-12-23 |
| NCT06380738AstraZenecaReal-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) | 2027-02-14 |
| NCT07560215AstraZenecaPROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC).
This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve progression-free survival and overall survival against a background of existing prostate cancer treatments.
ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC) patients who have had rising PSA after surgical or medical castration but have no evidence of metastases.
All patients participating in this clinical trial will receive existing prostate cancer treatments in addition to trial therapy.
Half the patients will receive ZD4054 (Zibotentan) , and half the patients will receive placebo in addition to standard prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may slow the progression of the tumour.
No patients will be deprived of standard prostate cancer therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who answer TRUE to the following criteria may be eligible to participate in this study.
Exclusion Criteria:
Patients who answer TRUE to the following may NOT be eligible to participate in this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching Placebo
Drug: Palcebo
ZD4054 (Zibotentan)
Drug: ZD4054
10 mg once daily oral dose
Also known as: Zibotentan
Matching Plcebo oral tablet once daily
Overall Survival
Number of participants who have died at early analysis data cut off (DCO)
Time frame: From date of randomization until date of death, assessed up to 33 months
Progression Free Survival
Number of participants who have a progression event at the early analysis DCO, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline
Time frame: Participants were followed up for progression every 4 weeks for the first 16 weeks then every 16 weeks
Health Related Quality of Life
Time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks
Time to Prostate-specific Antigen (PSA) Progression
Time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks
Time to Symptomatic Progression
Time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks
2577 patients with hormone-resistant prostate cancer patients and bone metastasis were recruited between 15th January 2008 and 3rd May 2011
| Milestone | ZD4054 | Placebo |
|---|---|---|
| Started | 705 | 716 |
| Patients received treatment | 703 | 712 |
| Completed | 0 | 0 |
| Not completed | 705 | 716 |
| Withdrew: Adverse event | 164 | 44 |
| Withdrew: Withdrawal by subject | 42 | 46 |
| Withdrew: Protocol violation | 4 | 11 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Other termination reason | 493 | 613 |
Number of participants who have died at early analysis data cut off (DCO)
| Participants | ZD4054 | Placebo |
|---|---|---|
| Overall Survival | 40 | 39 |
Number of participants who have a progression event at the early analysis DCO, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline
| Participants | ZD4054 | Placebo |
|---|---|---|
| Progression Free Survival | 131 | 162 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZD4054 | — | 148/703 (21.1%) | 531/703 (75.5%) |
| Placebo | — | 138/712 (19.4%) | 392/712 (55.1%) |
| Event | ZD4054 | Placebo |
|---|---|---|
| Cardiac FailureCardiac disorders | 9/703 | 3/712 |
| PneumoniaInfections and infestations | 7/703 | 5/712 |
| Angina PectorisCardiac disorders | 1/703 | 7/712 |
| HydronephrosisRenal and urinary disorders | 1/703 | 7/712 |
| Myocardial InfarctionCardiac disorders | 5/703 | 3/712 |
| Renal Failure AcuteRenal and urinary disorders | 5/703 | 2/712 |
| Gastric CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/703 | 5/712 |
| Atrial FibrillationCardiac disorders | 4/703 | 2/712 |
| Oedema PeripheralGeneral disorders | 4/703 | 0/712 |
| Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/703 | 1/712 |
| Event | ZD4054 | Placebo |
|---|---|---|
| Oedema PeripheralGeneral disorders | 268/703 | 88/712 |
| HeadacheNervous system disorders | 188/703 | 82/712 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 176/703 | 39/712 |
| FatigueGeneral disorders | 71/703 | 79/712 |
| ConstipationGastrointestinal disorders | 64/703 | 76/712 |
| DiarrhoeaGastrointestinal disorders | 46/703 | 63/712 |
| NauseaGastrointestinal disorders | 59/703 | 61/712 |
| RhinitisInfections and infestations | 56/703 | 17/712 |
| Urinary Tract InfectionInfections and infestations | 43/703 | 54/712 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 40/703 | 54/712 |
| Age Continuous(years) | ZD4054 | Placebo | Total |
|---|---|---|---|
| Overall | 72.4 ± 7.8 | 72.5 ± 7.8 | 72.45 ± 7.8 |
| Sex: Female, Male(Participants) | ZD4054 | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 705 | 716 | 1421 |
Showing the first 100 of 330 sites across 39 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2008, a primary completion of Jan 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZD4054